DHR on NYSE

Danaher Corporation

Logo: KarimKoueider, Public domain, via Wikimedia Commons5

American healthcare company

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics.3 From Wikipedia, CC BY-SA 4.0

$231.44 up 6.75 (3.01%)Price as of Oct 15, 2026 at 19:45 UTC

Last updated Oct 16, 2026.

Overview

1981Founded1

Compare with Roper Technologies, Ametek or Keysight Technologies, or pick any stock.

  • TickerDHR on NYSE1
  • Industryconglomerate1
  • HeadquartersWashington, D.C.1
  • Websitewww.danaher.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address2200 Pennsylvania Ave. N.W., Suite 800W, Washington, Dc 20037-17016
  • Filer categoryLarge accelerated filer6

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology (28% of 2024 revenues), which develops products for the development of therapeutics; life sciences (31% of 2024 revenues), which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics (41% of 2024 revenues), which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.1%Gross margin8
19.1%Operating margin8
14.7%Net margin8
2.9%Revenue growth, 20258
6.9%Return on equity8
0.35×Debt to equity8
$5.3BFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenue from Contract with Customer, Measurement, Recurring brought in 82% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. Revenue from Contract with Customer, Measurement, Recurring$20.1B882%up 4% from 2024
  2. Revenue from Contract with Customer, Measurement, Nonrecurring$4.4B818%down 2% from 2024
Products and services by year
Products and services202320242025
Revenue from Contract with Customer, Measurement, Recurring$18.7B$19.4B$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring$5.2B$4.5B$4.4B

Business segments

Diagnostics brought in 40% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. Diagnostics$9.9B840%up 2% from 2024
  2. Life Sciences$7.3B830%up 0% from 2024
  3. Biotechnology$7.3B830%up 8% from 2024
Business segments by year
Business segments202320242025
Diagnostics$9.6B$9.8B$9.9B
Life Sciences$7.1B$7.3B$7.3B
Biotechnology$7.2B$6.8B$7.3B

Regions

North America brought in 42% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. North America$10.4B842%up 1% from 2024
  2. High-Growth Markets$7.0B829%up 2% from 2024
  3. Western Europe$5.9B824%up 9% from 2024
  4. Other Developed Markets$1.3B85%down 0% from 2024
Regions by year
Regions202320242025
North America$10.0B$10.3B$10.4B
High-Growth Markets$7.2B$6.9B$7.0B
Western Europe$5.5B$5.5B$5.9B
Other Developed Markets$1.3B$1.3B$1.3B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue41¢$10.0B
  • Research and development7¢$1.6B
  • Selling, general and admin34¢$8.2B
  • Other costs2¢$443.0M
  • Income tax3¢$633.0M
  • Profit15¢$3.6B

Out of $24.6B in revenue.8

Where each dollar of operating cash went, fiscal 2025

  • Capital spending18¢$1.2B
  • Dividends paid14¢$878.0M
  • Share buybacks48¢$3.1B
  • Kept or used elsewhere20¢$1.3B

Out of $6.4B of cash from operations.8

Financial statements

Revenue91011128$24.6B in 2025+37% since 2019
0$10.0B$20.0B$30.0B2019: $17.9B$17.9B20192020: $22.3B$22.3B2020+24%2021: $24.8B$24.8B2021+11%2022: $26.6B$26.6B2022+7%2023: $23.9B$23.9B2023−10%2024: $23.9B$23.9B2024−0%2025: $24.6B$24.6B2025+3%
Gross profit91011128$14.5B in 2025+45% since 2019
0$5.0B$10.0B$15.0B$20.0B2019: $10.0B$10.0B20192020: $12.5B$12.5B2020+25%2021: $15.2B$15.2B2021+22%2022: $16.2B$16.2B2022+6%2023: $14.0B$14.0B2023−13%2024: $14.2B$14.2B2024+1%2025: $14.5B$14.5B2025+2%
Operating income91011128$4.7B in 2025+43% since 2019
0$2.0B$4.0B$6.0B$8.0B2019: $3.3B$3.3B20192020: $4.2B$4.2B2020+29%2021: $6.4B$6.4B2021+51%2022: $7.5B$7.5B2022+18%2023: $5.2B$5.2B2023−31%2024: $4.9B$4.9B2024−7%2025: $4.7B$4.7B2025−4%
Net income91011128$3.6B in 2025+20% since 2019
0$2.0B$4.0B$6.0B$8.0B2019: $3.0B$3.0B20192020: $3.6B$3.6B2020+21%2021: $6.4B$6.4B2021+76%2022: $7.2B$7.2B2022+12%2023: $4.8B$4.8B2023−34%2024: $3.9B$3.9B2024−18%2025: $3.6B$3.6B2025−7%

Every line of the income statement in the latest annual report, as filed.8

Period ending2025-12-312024-12-312023-12-31
Sales$24.6B$23.9B$23.9B
Cost of sales-$10.0B-$9.7B-$9.9B
Gross profit$14.5B$14.2B$14.0B
Selling, general and administrative expenses-$8.2B-$7.8B-$7.3B
Research and development expenses-$1.6B-$1.6B-$1.5B
Operating profit$4.7B$4.9B$5.2B
Other income (expense), net-$222.0M-$56.0M-$175.0M
Interest expense-$265.0M-$278.0M-$286.0M
Interest income$30.0M$117.0M$303.0M
Earnings from continuing operations before income taxes$4.2B$4.6B$5.0B
Income taxes-$633.0M-$747.0M-$823.0M
Net earnings from continuing operations$3.6B$3.9B$4.2B
Earnings from discontinued operations, net of income taxes$14.0M$0$543.0M
Net earnings$3.6B$3.9B$4.8B
Mandatory convertible preferred stock dividends$0$0-$21.0M
Net earnings attributable to common stockholders$3.6B$3.9B$4.7B
Net earnings per common share from continuing operations, basic (in usd per share)$5$5$6
Net earnings per common share from continuing operations, diluted (in usd per share)$5$5$6
Net earnings per common share from discontinued operations, basic (in usd per share)$0$0$1
Net earnings per common share from discontinued operations, diluted (in usd per share)$0$0$1
Net earnings per common share, basic (in usd per share)$5.07$5.33$6.44
Net earnings per common share, diluted (in usd per share)$5.05$5.29$6.38
Basic (in shares)712.7M shares731.0M shares736.5M shares
Diluted (in shares)716.1M shares737.2M shares743.1M shares

Compare Danaher Corporation with another company

The story

Founded by Mitchell Rales and Steven Rales in 1981.1

Early years

The company's origins go back to DMG, Inc., a Massachusetts real estate investment trust organized in 1969. In 1978, DMG, Inc. was reorganized as a Florida corporation and changed its name to Diversified Mortgage Investors, Inc. In 1983, the Stephen M. Rales and Mitchell P. Rales invested in the company, which at that time was invested in retirement home developments, they then replaced the existing management in a bitter proxy battle.

In 1984, the company adopted the name Danaher and reincorporated under the Delaware General Corporation Law. The name came from a river in Montana.

In 1985, the Rales brothers offered $400 million in a hostile bid for Scott Fetzer Company but lost out to Berkshire Hathaway.

In June 1986, Danaher acquired Chicago Pneumatic in a hostile takeover, offering $60.8 million for the 32% of the company not already owned. The company had merged in July 1984 with a sister company, the Jacobs Manufacturing Co., and had purchased Matco Tools in April 1981.

In June 1987, Danaher sold Chicago Pneumatic while retaining Jacobs, including its Matco Tools Division. Jacobs' name was changed to Matco Tools Corp. In November 1991, the other divisions within Jacobs were established as separate operating companies. In January 1993, Danaher formed NMTC, Inc., which acquired a substantial portion of the assets of MTC, including the existing distributorship agreements of MTC.

In 1986, Danaher added Qualitrol to its instrumentation unit, including Gilbarco Veeder-Root's underground fuel storage sensors, Dynapar's motion sensors, and pressure measurement and temperature measurement instruments used on the electrical transformer industry.

1990–2000

In 1990, Danaher acquired Easco Hand Tools Inc. Danaher was selected as exclusive supplier of hand tools for Sears. In 1994, Danaher acquired Armstrong Tools, the makers of tool brands Armstrong, Allen, and others.

In 1995, Danaher acquired Hengstler GmbH, a manufacturer of counters, printers, relays, and high-precision rotational sensors. Hengstler was Danaher's first acquisition headquartered outside the United States.

Read the full text

In 1999, the company acquired Hach Company, involved in water and wastewater—and analytics, for $325 million.

2001–2010

In 2000, H. Lawrence Culp Jr. was named CEO of Danaher; he had joined the company in 1990.

Danaher acquired Trojan Technologies, an environmental engineering firm, in 2004.

Danaher also acquired UK-based West Instruments, which provides control and measurement instrumentation and services for the global industrial and process markets.

Danaher announced its agreement to acquire the Gendex division from DENTSPLY International on

December 11, 2003, with the acquisition closing in early 2004, integrating this dental imaging company into Danaher's growing dental portfolio.

PMA, a German manufacturer of control and measurement instrumentation, was acquired in April 2005.

In July 2005, Danaher acquired Leica Microsystems, which manufactures products for applications requiring microscopic imaging, measurement and analysis and offers management systems for biotechnology and medicine, as well as the science of raw materials and industrial quality assurance.

In early 2007, Danaher acquired Vision Systems, which manufactures and markets automated instruments, antibodies and biochemical reagents for biopsy-based detection of cancer and infectious diseases, for $520 million.

In July 2007, Danaher acquired ChemTreat.

In November 2007, Danaher purchased Tektronix for US$2.85 billion.

In 2009, Danaher acquired the Analytical Technologies business unit of MDS, including a 50% interest in AB SCIEX, for US$650 million. In February 2010, Danaher acquired the remaining 50% ownership position in AB SCIEX from Life Technologies for US$450 million.

2011–2020

In 2011, Danaher acquired Beckman Coulter, which was divided into a diagnostics segment and a life sciences segment.

In January 2012, Danaher sold Accu-sort to Datalogic.

In December 2012, Danaher acquired Navman Wireless, a provider of on-demand fleet and asset management technology.

In February 2013, Danaher and Cooper Industries sold their joint venture, Apex Tool Group, to Bain Capital for $1.6 billion.

In September 2014, Danaher acquired Nobel Biocare for $2.2 billion.

Effective March 1, 2015, H. Lawrence Culp Jr. resigned as CEO of Danaher.

In July 2015, Danaher combined its communications unit with NetScout Systems.

In August 2015, Danaher acquired Pall Corporation for $13.8 billion.

In June 2016, Danaher completed the corporate spin-off of Fortive, which included Matco and AMMCO-COATS. In September of the same year, the company announced it would acquire Cepheid for $4 billion including debt.

In October 2016, Danaher acquired Phenomenex for $700 million to expand in life sciences.

In October 2017, Danaher announced the acquisition of scientific informatics company ID Business Solutions Ltd. (IDBS). IDBS became part of Danaher's Life Sciences platform.

In March 2018, Danaher acquired Integrated DNA Technologies for an estimated $1.9 billion.

In July 2018, Danaher announced its intention to spin off its Dental segment into a public company, later named Envista Holdings Corporation. The corporate spin-off was completed in December 2019.

In March 2020, Integrated DNA Technologies, a subsidiary of the company, manufactured components for COVID-19 testing.

In March 2020, Danaher acquired the biopharma business of General Electric, a global provider of technologies and services related to the development, manufacture, and delivery of vaccines, diagnostics, and therapeutics to customers in organizations including academia, biotechnology, and drug manufacturing, for $21.4 billion and was rebranded as Cytiva. The GE deal raised monopoly concerns. The Federal Trade Commission conditionally approved the deal on the grounds that Danaher sold some biotechnology assets. In a second deal, Danaher's biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards businesses were sold to Sartorius AG for approximately $825 million. The Cytiva name is derived from 'cyto' meaning 'cell' in Greek, and 'iva' a Latin suffix meaning 'doing' and 'capable of'.

Effective September 2020, Tom Joyce retired as CEO of the company; he was replaced by Executive Vice President Rainer Blair.

2021–present

In June 2021, Precision Nanosystems was acquired by Cytiva.

In August 2021, Danaher acquired Aldevron, which produces mRNA and proteins used in mRNA vaccines, for $9.6 billion in cash.

In May 2023, Pall Corporation merged with Cytiva to create a new Biotechnology Group within Danaher; at that time Cytiva employed more than 16,000 associates in over 40 countries.

Also in September 2022, Danaher announced its intention to spin off its Environmental & Applied Solutions segment; in February 2023, it was named Veralto and the corporate spin-off was completed in September 2023. The division included Aquatic Informatics, ChemTreat, Esko, Hach Company, Linx, McCrometer, OTT HydroMet, Pantone, Sea-Bird Scientific, Trojan Technologies, Videojet, XOS, and X-Rite.

In December 2023, Danaher acquired Abcam for approximately $5.7 billion.

In June 2024, the Food and Drug Administration granted marketing approval to Danaher's Cepheid unit for a rapid test for hepatitis C. Using a blood sample from a fingertip, the rapid test detects the virus's RNA and delivers results in less than roughly an hour, as opposed to requiring a sample to be sent to a lab.

In August 2024, the company acquired GeneData. In February 2026, Danaher announced it would acquire Masimo for $10 billion.

From Wikipedia’s article on Danaher Corporation, shared under CC BY-SA 4.0.7

Leadership

Who has led Danaher Corporation, and when. Pick a name to see everywhere that person has worked.

Products and brands

Life sciences

Abcam

Beckman Coulter - Life Sciences

Cytiva

Integrated DNA Technologies

Read the full text

Leica Microsystems

Molecular Devices

Pall Corporation

SCIEX

Diagnostics

Beckman Coulter - Diagnostics

Cepheid

Leica Biosystems

Radiometer

From Wikipedia’s article on Danaher Corporation, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Owners

Subsidiaries

  • AB Sciex
  • Danaher (Australia)
  • Danaher (China)
  • Danaher (Germany)
  • Danaher (Singapore)
  • Danaher (Sweden)
  • Danaher (Switzerland)
  • Danaher (United Kingdom)
  • Nobel Biocare
  • Teletrac
  • Beckman Coulter since 2012
  • Pall Corporation since Aug 31, 2015
  • Phenomenex since Oct 11, 2016
  • Integrated DNA Technologies since Mar 19, 2018

From Wikidata.1

Acquisitions

  1. Mar 19, 2018Integrated DNA Technologies became a subsidiary1
  2. Oct 11, 2016Acquired Phenomenex1
  3. Aug 31, 2015Acquired Pall Corporation1
  4. 2012Beckman Coulter became a subsidiary1
  5. 2004Acquired KaVo Dental1

Timeline

  1. 1981Founded Founded1

Recent filings

  1. Oct 14, 20264
  2. Oct 14, 20264
  3. Oct 13, 20268-K
  4. Oct 2, 20263
  5. Oct 2, 20263
  6. Sep 30, 202625-NSE
  7. Aug 24, 20264
  8. Aug 21, 2026144
  9. Aug 6, 20264
  10. Aug 6, 20264
  11. Aug 6, 20264
  12. Aug 6, 20264
  13. Aug 6, 20264
  14. Aug 6, 20264
  15. Aug 6, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2